Whole Genome Sequencing (WGS) on IVF Embryos and Individual Patients (EmbryoWGS)

Study of the Effect of Paternal Age on de Novo Mutation Rate by Using Whole Genome Sequencing of IVF Embryos

This research project aims to utilise recent advances in whole genome sequencing of preimplantation genetic diagnosis embryos to investigate the impact of paternal age on de novo mutation rates in IVF embryos. Embryos that are deemed unsuitable for transfer following preimplantation genetic testing for monogenic/single gene disorders (PGT-M) due to the detection of genetic abnormalities will be utilized for this study. These embryos will undergo re-biopsy, and both the biopsied samples as well as the remaining embryo tissue will be subject to whole genome sequencing. This will allow the assessment of de novo mutation rates based on the paternal age.

Study Overview

• Status: Recruiting
• Conditions: Fertility Issues; Single-Gene Defects
• Intervention / Treatment: Other: Embryo genome sequencing; Other: Parents genome sequencing

Detailed Description

This project proposes a paired non-inferiority trial utilizing the retrospective testing of research embryos to establish the optimized parameters for amplified trophectoderm biopsy and whole genome sequencing compared to traditional preimplantation genetic testing for aneuploidy (PGT-A).

The primary outcome is the de novo mutation rate, which will be compared between embryos subjected to trophectoderm biopsy and whole genome sequencing versus reanalysis with Sanger sequencing. Trio testing will be performed for each embryo using DNA from the genetic parents in addition to embryo. The study will compare cases that include couples with at least one embryo deemed unsuitable for transfer. A paired study design will be used, with embryos from each couple split into two arms - one subjected to trophectoderm biopsy and whole genome sequencing, the other to reanalysis with targeted sequencing.

Biopsied trophectoderm samples and the remaining embryo tissues from the whole genome sequencing arm will undergo sequencing. Sequencing will also be performed on DNA samples from each genetic parent.

Derivation of de novo mutation rates is a key goal, as these provide insights into effects of paternal age and other factors on germline mutations in preimplantation embryos, increasing the knowledge of the risks associated with advanced paternal age. Secondary metrics will be investigated to supplement the analysis, including clean reads and clean bases indicating the amount of high-quality data for the source templates. Mapping rate, unique rate and duplicate rate, assessing data accuracy and quality. Comparison of multiple metrics will determine the optimized parameters for performing amplified trophectoderm biopsy and whole genome sequencing. This can then inform future research and clinical studies.

The de novo mutation rate will be derived by modelling the observed mutation rate as a function of parental ages, specifically the paternal age. Whole genome sequencing of embryo samples as well as both parents will identify raw numbers of de novo mutations. The paternal age coefficient for the de novo mutation rate will be calculated using a regression model with the number of de novo mutations as the dependent variable and paternal age as the key independent variable. Covariates like maternal age and sequencing quality metrics will also be included to account for potential confounding factors. The regression model will determine the increase in de novo mutations per year of paternal age, providing the paternal age coefficient. Comparing embryos from older and younger males will reveal differences in mutation rates. The overall model will establish the quantitative relationship between paternal age and de novo mutations in preimplantation embryos based on the study's whole genome sequencing data.

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Santiago Munné, PhD; Phone Number: +1-646-2072897; Email: santiago.munne@gmail.com

Study Locations

• Turkey
  • Okmeydani-Sisli
    • Istanbul, Okmeydani-Sisli, Turkey, 34385
      • Recruiting
      • Preimplantation Genetic Testing Unit ART and Reproductive Genetics Unit, Memorial Sisli Hospital
      • Contact: Semra Kahraman, M.D.; Phone Number: 90 212 314 6666
      • Contact: Murat Cetinkaya, M.D., PhD; Phone Number: +90 533 266 42 24; Email: muratcetinkaya01@gmail.com
• United States
  • New York
    • New York, New York, United States, 10024
      • Not yet recruiting
      • Neway Fertility
  • Oregon
    • Portland, Oregon, United States, 97205
      • Not yet recruiting
      • ORM Fertility
  • Washington
    • Kirkland, Washington, United States, 98034
      • Not yet recruiting
      • Poma Fertility

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 30 years (Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Couples undergoing IVF with 1≥ embryo sample unsuitable for transfer due to genetic or chromosome abnormalities.

Description

Couples undergoing IVF with 1≥ embryo sample unsuitable for transfer due to genetic or chromosome abnormalities.

Cases with parental DNA available directly or consenting follow-up.

Exclusion Criteria:

• Female patients with low ovarian reserve (< 10 follicles or FSH>10, AMH <1).

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Age >18yrs; The study will compare embryos from >50 couples and their embryo samples flagged not suitable for transfer from deidentified couples with date of birth required.

Other: Embryo genome sequencing; This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.; Other: Parents genome sequencing; Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
De novo mutation rates	Metrics for investigation include: clean reads, clean bases (Mp), mapping rate, unique rate, duplicate rate, mismatch rate, average sequencing depth, Ti/Tv (Transition/ Transversion) ratio, true-positive rate, false-positive rate, false-negative rate which enables the derivation of de novo mutation rates.	Month 6
Variant pathogenicity, Zygosity and mode of inheritance	Variant pathogenicity; the zygosity and mode of inheritance will be assessed and documented for validation of variant calls for heritable and non-inherited variants. There will be an examination of the sequencing data from the embryo cohort by using the parental genomes as a validation reference. Initially this will focus on single nucleotide polymorphisms (SNPs) and small insertions/deletions (Indels).	Month 6

Collaborators and Investigators

• Sponsor: GenEmbryomics Pty. Ltd
• Investigators: Principal Investigator: Nicholas Murphy, PhD, GenEmbryomics Pty. Ltd

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2023
• Primary Completion (Estimated): March 1, 2024
• Study Completion (Estimated): August 1, 2024

Study Registration Dates

• First Submitted: February 13, 2023
• First Submitted That Met QC Criteria: February 13, 2023
• First Posted (Actual): February 22, 2023

Study Record Updates

• Last Update Posted (Actual): September 25, 2023
• Last Update Submitted That Met QC Criteria: September 21, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Genome Sequencing IVF
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Infertility; Genetic Diseases, Inborn
• Other Study ID Numbers: RP-GE_02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Data sharing plan will be defined once results are available.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No